News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AntriaBio To Present At The Third Annual Marcum MicroCap Conference On Thursday, May 29, 2014


5/22/2014 9:01:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MENLO PARK, CA--(Marketwired - May 22, 2014) - AntriaBio, Inc. (OTCQB: ANTB) a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic disease, announced today that Nevan Elam, Chief Executive Officer, will be presenting at the Third Annual Marcum MicroCap Conference at 3:00 p.m. Eastern Time on Thursday, May 29, 2014 at the Grand Hyatt New York.

Mr. Elam will review the Company's business outlook and expected near-term development advancements of its lead product candidate AB101, a once-weekly basal insulin for the treatment of diabetes. Also, Mr. Elam will be available to participate in one-on-one meetings with investors attending the conference.

A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website at www.antriabio.com. The webcast presentation will be archived on AntriaBio's website for 90 days following the event.

About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutics to treat patients with diabetes and metabolic disease. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit: www.antriabio.com.

Forward-Looking Statements
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.


AntriaBio, Inc. Contact:
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
(908) 938-1475



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
AntriaBio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES